From Longevity Wiki
MIT-001 (also known as NecroX-7 or LC28-0126)
Formula C24H29N3O3S
Mol Weight 439.57
CAS No. 1120332-55-9

MIT-001 (also known as NecroX-7 or LC28-0126) is a reactive oxygen species scavenger and a necrosis inhibitor being developed for the treatment of various conditions caused by oxidative stress.[1] It is also a HMGB1 (high-mobility group box 1) inhibitor.[2]

It was reported that MIT-001 has an anti-inflammatory effect on the ovaries of old mice and recovers ovarian function. The number of oocytes per ovary increased two-fold in MIT-001-treated old mice.[3]

Multiple administrations of LC28-0126 exhibited a dose-proportional pharmacokinetic profile and were well tolerated at a dose range of 3–30 mg.[4] identifier: NCT03196804

NecroX-7 has demonstrated therapeutic efficacies in a wide range of diseases including graft-versus-host disease (GVHD),[5] improved chronic colitis by attenuating the mRNA expression of pro-inflammatory cytokines such as TNF-α,[6] demonstrated potential as a medication for neurological disorders with its neuroprotective, anti-inflammatory, and anti-necroptotic effects [7]

  1. Kim, H. J., Koo, S. Y., Ahn, B. H., Park, O., Park, D. H., Seo, D. O., ... & Kim, S. H. (2010). NecroX as a novel class of mitochondrial reactive oxygen species and ONOO⁻ scavenger. Archives of pharmacal research, 33(11), 1813-1823. PMID: 21116785 DOI: 10.1007/s12272-010-1114-4
  2. Plemmenos, G., Tzimogianni, V., Fili, C., & Piperi, C. (2023). Contributing Role of High Mobility Group Box 1 Signaling in Oral Cancer Development and Therapy. Life, 13(7), 1577. PMID: 37511951 PMC10381251 DOI: 10.3390/life13071577
  3. Kang M-H, Kim YJ, Cho MJ, Jang J, Koo YD, Kim SH, Lee JH. (2023). Mitigating Age-Related Ovarian Dysfunction with the Anti-Inflammatory Agent MIT-001. International Journal of Molecular Sciences; 24(20):15158.
  4. Kim, E., Hwang, I., Lee, S., Oh, J., Chung, H., Jin, M., ... & Yu, K. S. (2020). Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects. Clinical Therapeutics, 42(10), 1946-1954. DOI: 10.1016/j.clinthera.2020.08.011
  5. Im, K. I., Kim, N., Lim, J. Y., Nam, Y. S., Lee, E. S., Kim, E. J., ... & Cho, S. G. (2015). The free radical scavenger NecroX-7 attenuates acute graft-versus-host disease via reciprocal regulation of Th1/regulatory T cells and inhibition of HMGB1 release. The Journal of Immunology, 194(11), 5223-5232.PMID: 25911749 PMC4432727 DOI: 10.4049/jimmunol.1402609
  6. Kim, D., Koo, J. S., Kim, S. H., Park, Y. S., Choe, J. W., Kim, S. Y., ... & Yim, H. J. (2023). The Effect of Necrosis Inhibitor on Dextran Sulfate Sodium Induced Chronic Colitis Model in Mice. Pharmaceutics, 15(1), 222. PMC9862178
  7. Roh, Y., Lee, S. B., Kim, M., Kim, M. H., Kim, H. J., & Cho, K. O. (2023). Alleviation of hippocampal necroptosis and neuroinflammation by NecroX-7 treatment after acute seizures. Frontiers in Pharmacology, 14. PMID: 37601059 PMC10433749 DOI: 10.3389/fphar.2023.1187819